| ²é¿´: 171 | »Ø¸´: 0 | |||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | |||
[½»Á÷]
»ÔÈðÒ©ÎﰲȫºÍ·çÏÕ¹ÜÀíÊîÆÚ°à£¨09Äê7Ô¿ª°à£¬È«³ÌÁãÊÕ·Ñ£©
|
|||
|
¹Ù·½ÍøÕ¾£ºhttp://ydhd.shnu.edu.cn/pfizer Ò»¡¢ÅàÑøÄ¿±ê£º ±¾ÊîÆÚ°àÖ¼ÔÚ¹¹ÖþÒ½Ò©Ñз¢È˲ŵÄÅàÑøÓë³É³¤Æ½Ì¨£¬°ïÖúÓ¦½ì´óѧÉúÌá¸ß×ÔÉí¾ºÕùÁ¦£¬Íƶ¯ÖйúÖÆÒ©ÐÐÒµµÄ¿ìËÙ½¡¿µ·¢Õ¹¡£ ¶þ¡¢ÕÐÉú¶ÔÏó£º Ó¦½ì´óѧÉú£¨½øÈëʵϰÆÚµÄ±¾¿ÆÉú¡¢Ñо¿Éú£©ÖжÔÒ©ÎﰲȫºÍ·çÏÕ¹ÜÀíÓÐÐËȤ»òÓÐÒâ´ÓʸÃÖ°ÒµÕߣ¬ÓÅÏÈ¿¼ÂÇÁÙ´²Ò½Ñ§£¬Ò©Àíѧ£¬Á÷Ðв¡Ñ§£¬ÉúÎïͳ¼ÆµÈרҵµÄѧÉú¡£ Èý¡¢ÕÐÉúÈËÊý£º 2009ÊׯÚÊîÆÚ°àÔ¤ÊÕѧԱ40ÈË¡£ ËÄ¡¢ÊÚ¿Îʱ¼ä£º 2009Äê7ÔÂÖÐÑ®ÖÁ8ÔÂÏÂÑ®£¬Ã¿ÖÜÒ»ÖÁÖÜÎå¡£ Îå¡¢Êڿεص㣺 ÉϺ£Ê¦·¶´óѧ£¨ÉϺ£ÊÐÐì»ãÇø¹ðÁÖ·100ºÅ£©ÊýÀíѧԺ¡£ Áù¡¢¿Î³ÌÄÚÈÝ£º ±¾Êî¼Ù°à½«²ÉÓÃÓ¢ÎĽ̲ļ°ÖÐÓ¢ÎÄÊڿεÄģʽ£¬ÏµÍ³µØ½éÉÜÒ©Îᆵ½äѧµÄ»ù´¡ÖªÊ¶¼°È«Çò²»Á¼·´Ó¦µÄÐźÅÍÚ¾òµÄÏȽø·½·¨£¬²¢½áºÏʵÀý½²ÊöÒ©Îï·çÏÕ¹ÜÀíµÄÖØÒªÐÔ¼°Êµ¼ùÒâÒ塣ǿµ÷·¨¹æ¡¢ÐÅϢϵͳµÄ½¨ÉèÒÔ¼°Êý¾Ý½»»»µÄ¼ÛÖµ¡£ • The Basis of Pharmacovigilance£¨Ò©Îᆵ½äѧ¸ÅÊö£© • Signal generation: Data Collection & Data Mining£¨ÐźŵIJúÉú£ºÊý¾ÝÊÕ¼¯ºÍÍÚ¾ò£© • Adverse Reactions of System Organ Classes£¨²»Í¬Æ÷¹ÙµÄ²»Á¼·´Ó¦£© • Risks & Benefits Assessment£¨·çÏÕÐ§ÒæÆÀ¹À£© • Future Directions of Pharmacovigilance£¨Õ¹Íû£© • Pharmacovigilance in Pfizer£¨»ÔÈð²»Á¼·´Ó¦¼à²â¸Åò£© Æß¡¢½áÒµÓëÖ¤Ê飺 ʵѵÄÚÈݽøÐÐϵͳ¿¼ºËºÏ¸ñÕߣ¬°ä·¢¡¶»ÔÈðÒ©ÎﰲȫºÍ·çÏÕ¹ÜÀíÊîÆÚ°à¡·Ö¤Ê飬Åàѵ¼¨ÓÅÕߣ¬½«Óлú»á½øÈë»ÔÈð£¨Öйú£©Ñз¢ÖÐÐÄ»òÆäËûºÏ×÷µ¥Î»Ïà¹Ø²¿ÃÅʵϰ¡£ °Ë¡¢ÊÕ·Ñ£º È«³ÌÁã·ÑÓᣠÉϺ£¸ßУѧԱÐè×ÔÐнâ¾öסËÞ¡£ ÍâµØÑ§Ô±ÓÉÉϺ£Ê¦·¶´óѧÌṩסËÞ¡£ ¾Å¡¢±¨Ãû·½·¨£º ÔÚÏßÉêÇ룺http://ydhd.shnu.edu.cn/pfizer ²¢·¢Ë͵ç×Ó°æµÄ¼òÀú£¨ÖÐÓ¢ÎÄ£©¡¢ÔÚ¶ÁѧУ³É¼¨µ¥¡¢»ñ½±Ö¤ÊéÖÁ£ºChinaCPWTalent@p_zer.com Ê®¡¢±¨Ãûʱ¼ä£º ¼´ÈÕÆðÖÁ2009Äê6ÔÂ25ÈÕ Ê®Ò»¡¢×Éѯ·½Ê½£º ×ÉѯEmail£ºjzhu@shnu.edu.cn ÁªÏµÈË£ºÖìÀÏʦ |
» ²ÂÄãϲ»¶
С°×¾ÈÖú,ELISAÊÔ¼ÁºÐÄ£ÐÍ×éºÍÕý³£×éûÓÐÇø±ð
ÒѾÓÐ4È˻ظ´
£¬
ÒѾÓÐ1È˻ظ´
Ô¤·ÀҽѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ219È˻ظ´
ÖÐҩѧ/Ò©Àíѧ²©Ê¿ÉêÇ룬¾È¾Èº¢×Ó°É
ÒѾÓÐ3È˻ظ´
DEAE-52Öù²ãÎöÖù¹ýÖù×ÓÏà¹Ø×Éѯ¡«
ÒѾÓÐ1È˻ظ´
×î½üFrontier in EndocrinologyÓиö¾«×ÓÑо¿Ïà¹ØµÄÖ÷Ìâר¿¯£¬ÓкÏÊʸå¼þ¿É¹Ø×¢¡£
ÒѾÓÐ1È˻ظ´
ÉúÐÅÓѺÃÔÓÖ¾ÍÆ¼ö---Frontiers in Genetics
ÒѾÓÐ0È˻ظ´
26Ä격ʿÉêÇë
ÒѾÓÐ12È˻ظ´
26Ä꿼ÑÐ
ÒѾÓÐ12È˻ظ´














»Ø¸´´ËÂ¥